Quest Diagnostics Incorporated (NYSE:DGX) Q1 2024 Earnings Call Transcript

Page 1 of 5

Quest Diagnostics Incorporated (NYSE:DGX) Q1 2024 Earnings Call Transcript April 23, 2024

Quest Diagnostics Incorporated beats earnings expectations. Reported EPS is $2.04, expectations were $1.86. DGX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Welcome to the Quest Diagnostics First Quarter 2024 Conference Call. At the request of the company, this call is being recorded. The entire contents of the call, including the presentation and question-and-answer session that will follow, are the copyrighted property of Quest Diagnostics with all rights reserved. Any redistribution, retransmission or rebroadcast of this call in any form without the written consent of Quest Diagnostics is strictly prohibited. Now I’d like to introduce Shawn Bevec, Vice President of Investor Relations for Quest Diagnostics. Sir, please go ahead.

Shawn Bevec: Thank you, and good morning. I’m joined by Jim Davis, our Chairman, Chief Executive Officer and President; and Sam Samad, our Chief Financial Officer. During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics’ future results include, but are not limited to, those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K. For this call, references to reported EPS refer to reported diluted EPS and references to adjusted EPS refer to adjusted diluted EPS.

Any references to base business, testing, revenues or volumes refer to the performance of our business excluding COVID-19 testing. Growth rates associated with our long-term outlook projections, including consolidated revenue growth, revenue growth from acquisitions, organic revenue growth and adjusted earnings growth are compound annual growth rates. Finally, revenue growth rates from acquisitions will be measured against our base business. Now here is Jim Davis.

Jim Davis: Thanks, Shawn, and good morning everyone. In the first quarter, we delivered nearly 6% base business revenue growth, continuing the strong momentum of recent quarters. We also grew total revenues for the first time since the height of the pandemic nearly three years ago. Our strong commercial focus on physicians and hospitals, combined with our broad health plan access, enabled us to take advantage of sustained high rates of healthcare utilization and drive new customer growth. Our investments in advanced diagnostics also enabled double-digit growth within multiple key clinical areas, including brain health, women’s health, and advanced cardiometabolic health. In addition, our Invigorate initiative, which includes ongoing investments in automation and AI, continued to improve productivity as well as service levels and quality.

Given the strength of our business, we are raising our guidance for the full year. Before turning to highlights from the quarter, I’d like to briefly discuss the FDA’s proposed rule to regulate laboratory-developed testing services. We still encourage the administration to withdraw the proposed rule and engage in advancing appropriate legislation that preserves the critical role of laboratory diagnostics. We are disappointed that the FDA continues to move forward with this regulation, which we believe, if enacted, will compromise patient access to critical lab testing, slow diagnostic innovation, and add unnecessary healthcare costs. We also believe that the rule raises serious legal issues, including that the FDA lacks the statutory authority to unilaterally regulate these services.

While we will be prepared to comply with the rule, we will continue to work with our trade association, ACLA, on potential next steps. Now I’ll recap our strategy and discuss highlights from the first quarter. Then Sam will provide detail on our financial results and talk about our updated financial guidance for 2024. Our strategy to drive growth is focused on delivering solutions that meet the evolving needs of our core customers, physicians, hospitals, and consumers. We enable growth across our customer channels through advanced diagnostics with an intense focus on faster-growing clinical areas, including brain health and molecular genomics and oncology. In addition, acquisitions are a key growth driver, with an emphasis on accretive hospital outreach purchases as well as smaller, independent labs.

Our strategy also includes driving operational improvements across the business, with the strategic deployment of automation and AI to improve quality, service, efficiency, and the workforce experience. Here are a few key updates on the progress we’ve made in each of these areas. In Physician Lab Services, we delivered high single-digit based business revenue growth driven by sustained high healthcare utilization, overall market growth and share gains. This growth also reflects new customer wins and our strengthening relationships with physician practices of all sizes, including large multi-specialty physician groups and those owned by large retailers. A significant driver of our success in the physician channel is our broad health plan access, as approximately 90% of health plan members in the U.S. have access to laboratory services at Quest Diagnostics.

Health Plans value our size, scale, and innovation. We partner closely with them to reduce laboratory costs through programs that redirect volume from hospital outreach labs and out-of-network labs, which often charge significantly higher prices than we do, raising healthcare costs for patients and employers. We also remain disciplined in our pricing strategy as we increase our investments in improving the customer experience, such as through digital platform enhancements and adjustments to Frontline Pay. As we highlighted previously, we successfully renegotiated our large health plan contracts that were up for renewal last year. In addition, more than 50% of our health plan revenues now have some type of value-based incentive. In Physician Services, our recent acquisition of Lenco, an independent lab in New York, also contributed to growth in the quarter.

Our M&A pipeline continues to be robust, and we are making progress with several promising opportunities. In Hospital Lab Services, we grew base business revenues by mid-single digits. Hospital reference testing, in particular, continued to grow faster than pre-pandemic trends, maintaining the momentum from last year. Hospitals are sending us more reference testing, largely because of our innovation, our quality, and our value. They also face persistent challenges with staffing certain roles in specialized fields like histology, microbiology, and cytotechnology, which we can more easily fill with our talent and our technology. In general, as hospitals face both staffing and cost challenges, they continue to reevaluate their lab strategies. Additionally, as the cost of capital continues to rise, some are revisiting their investment priorities and are directing more capital into other clinical areas that generate better returns.

Quest provides hospitals with a range of ways to help optimize lab operations, whether through reference testing, savings and efficiencies through professional lab services, or access to capital by selling their outreach programs. Many hospitals and health system leaders are approaching us with a heightened sense of urgency for help with their lab strategies. As a result, our pipeline of both PLS and outreach opportunities remains very strong. Consumer-initiated testing revenues grew double digits, while base business revenues nearly doubled, building on the gains that we delivered last year from our consumer-facing platform, questhealth.com. Some of our most popular test categories included general health panels, STDs, and tuberculosis testing.

A healthcare specialist providing a risk assessment for a patient.

We also continue to expand our test menu, such as with our launch of PFAS testing for assessing potential exposure to dangerous forever chemicals, and are extending our reach through various channel partners. In Advanced Diagnostics, we generated strong double-digit revenue growth within several key clinical areas, including brain health, women’s health, particularly prenatal and hereditary genetics, and advanced cardiometabolic health. Growth in brain health was driven largely by our Alzheimer’s disease portfolio of tests, which includes our Quest AD-Detect blood tests for early risk assessment of Alzheimer’s disease and our CSF Tests for diagnosing and monitoring. We are launching our Quest AD-Detect pTau-217 blood test to providers this week, and we intend to add additional biomarkers this year to further expand our menu.

In molecular genomics and oncology, we completed the validation of our Haystack MRD test in March and have oversubscribed our Haystack MRD Early Experience Program with nearly 20 leading cancer institutions as participants. The Early Experience Program is the final step to prepare for our broad national launch of the clinical test later this year. We are also excited about the opportunities in early blood-based cancer screening. This quarter, our Lewisville, Texas site received the first specimens for the PROMIS Clinical Trial on a liquid biopsy screening test for colorectal cancer from our partner, Universal DX. We look forward to supporting Universal’s efforts to gain U.S. regulatory approval for this test. Lastly, our STEP500 somatic tumor sequencing service, which helps providers select therapy for late-stage cancers based on tumor mutation profiles, is generating interest from large cancer centers.

Our investments in cancer screening, treatment selection, and monitoring are positioning us to be a leader in the MRD space and other fast-growth molecular genomics and oncology markets. Turning to operational excellence, our Invigorate program aims to deliver a targeted 3% annual cost savings and productivity improvements. During the quarter, we continued to deploy automation and AI to improve productivity as well as service levels and quality. For instance, we made progress creating what we term a digital front door, which will use AI in our website and service center kiosks to answer basic questions from patients, reducing workload on Phlebotomist and calls to our customer service team. We also recently automated elements of the specimen preparation process in several labs and expect to deploy these systems across other sites in 2024.

These systems make our front-end operations more efficient and improve quality while also freeing our employees to focus on other value-added work. Finally, I’d like to personally thank my Quest colleagues for delivering a superior customer experience. Our industry just celebrated Lab Week, which reminds us of the key role labs play at the heart of healthcare. I’m proud that our nearly 50,000 employees bring Quest’s purpose to life every day. Working together to create a healthier world, one life at a time. And with that, I’ll turn it over to Sam to provide more details on our performance and our 2024 guidance. Sam?

Sam Samad : Thanks, Jim. In the first quarter, consolidated revenues were $2.37 billion, up 1.5% versus the prior year, while base business revenues grew nearly 6%. Revenues for Diagnostic Information Services were up 1.7% compared to the prior year, reflecting strong growth in our base testing revenues, partially offset by lower revenues from COVID-19 testing services. Total volume measured by the number of requisitions, increased 1.6% versus the first quarter of 2023, with acquisitions contributing 60 basis points to total volume. Total base testing volumes grew 3.3% versus the prior year, despite the impact of severe weather in the first two weeks of January. During the quarter, weather negatively impacted volume growth by approximately 30 basis points.

Revenue per requisition was up slightly versus the prior year, driven primarily by an increase in the number of tests per rec and favorable test mix, largely offset by lower COVID-19 testing. Base business revenue per rec was up 2.6% due to an increase in the number of tests per rec and favorable test mix. Unit price reimbursement was flat. Reported operating income in the first quarter was $300 million, or 12.7% of revenues, compared to $305 million, or 13.1% of revenues last year. On an adjusted basis, operating income was $349 million or 14.8% of revenues compared to $350 million or 15% of revenues last year. Adjusted operating income was relatively consistent versus the prior year due to strong growth in the base business, largely offset by lower COVID-19 testing revenues, wage increases, and higher benefit costs.

Reported EPS was $1.72 in the quarter compared to $1.78 a year ago. Adjusted EPS was $2.04, flat versus the prior year. Cash from operations was $154 million in the first quarter versus $94 million in the prior year. Subsequent to the end of the first quarter, we repaid $300 million of senior notes which matured on April 1st. Turning to our updated full year 2024 guidance. Revenues are expected to be between $9.4 billion and $9.48 billion. Reported EPS expected to be in a range of $7.57 to $7.82, and adjusted EPS to be in a range of $8.72 to $8.97. Cash from operations is expected to be approximately $1.3 billion, and capital expenditures are expected to be approximately $420 million. The following are some key assumptions underlying our guidance to consider as you update your models.

COVID-19 testing revenues to decline approximately $175 million for the full year. In terms of M&A, our guidance only includes acquisitions that have been announced or closed to-date. No change to our expectation for dilution from Haystack Oncology of an incremental $0.20 to adjusted EPS for the full year. Operating margin to expand for the full year driven by volume growth and improved productivity. Net interest expense to be approximately $190 million. Weighted average share count to be flat compared to the end of 2023. While we are only one quarter into the year, given the strong volume trends in Q1, we have raised our adjusted EPS guidance by $0.10 at the midpoint, which more than offsets the $0.05 to $0.07 headwind we experienced from weather in January.

With that, I will now turn it back to Jim.

Jim Davis: Thanks, Sam. To summarize, our business delivered strong revenue growth across our core customer channels, physicians, hospitals, and consumers, building on trends from 2023. Our strong customer relationships, broad health plan access, and investments in advanced diagnostics are enabling us to take advantage of sustained high healthcare utilization and drive new customer growth. We are steadily improving productivity as well as service levels and quality, giving us confidence in improved profitability in 2024. Now we’d be happy to take your questions. Operator.

See also Top 25 States with Cheapest Gasoline Prices and 10 Best Alternatives to Nursing Homes and Assisted Living.

Q&A Session

Follow Quest Diagnostics Inc (NYSE:DGX)

Operator: Thank you. [Operator Instructions]. Our first question for today will come from Patrick Donnelly of Citi. Your line is open, sir.

Patrick Donnelly: Hey guys. Good morning. Thanks for taking the question. I want to focus on the margins Sam. Obviously, a big story throughout last year. Nice to see them come in a little bit better than expected this quarter. Can you talk about the moving pieces? It sounds like Haystack was as expected in terms of the dilution for the year. You are kind of maintaining that expectation. But can you talk about the better performance this quarter and then expectations as we work our way through the year, the right way to think about the cadence there? I just want to make sure we have that metric kind of ironed out as we think about the progress as we work our way through 2024 here.

Jim Davis : Yeah, sure Patrick, and good morning. So maybe the best way to look at it is think about it in terms of year-over-year. We were 14.8% operating margins in Q1 of this year compared to 15% last year. So some moving parts for you to consider and think about, because you can look at this in many different ways. But versus last year, obviously a big headwind in terms of COVID, both in terms of volumes, but also price. We had $90 million less COVID this quarter versus last year same quarter, at a much lower price as well, because we were getting reimbursed at $100 price back then. If you think about other smaller headwinds, I mean Haystack as you said, we still expect it to be $0.20 incremental dilution versus last year for the full year, well you saw that in Q1.

But then offsetting these headwinds, the biggest one being COVID, was base volume growth and productivity improvement. So we actually offset almost the majority of the COVID headwind through base improvement in terms of margins. The consumer-initiated testing business also expanded operating margins as well. We continue to see great momentum in that business and good improvement in profitability. Our base gross margins actually improved quite significantly from Q1 of last year, so very encouraged by the start that we’ve had and the momentum that we see going forward. In terms of cadence, I think to answer your second question, it’s I’d say normal seasonality that you would expect going forward. A step up in Q2 in terms of operating margins, maybe consistent operating margins to Q2 and Q3, and then a step down in Q4, which is, I would say normal pre-COVID seasonality for us.

Operator, next question.

Operator: Yes. The next question will come from Ann Hynes of Mizuho Securities. Your line is open.

Ann Hynes: Great, thanks. Good morning. So you beat consensus by 11%, but only raised EPS by 1% – I mean, I’m sorry 1%. Can you tell us what Q1 came in versus your internal expectations? And should we view that differential as conservatism, or is it something else we should consider as we model? Thanks.

Sam Samad : So let me start, Ann. Thank you for the question by the way. This is Sam, and Jim if you want to add anything as well, by all means. We beat in Q1, both in terms of versus external expectations, but also versus our own internal expectations. So we came in better. We had called out at the beginning of the year on the Q4 earnings call that we expect to see a $0.05 to $0.07 headwind from weather, in terms of EPS headwind from weather. That was at the time driven by the fact that really the first two weeks, three weeks of January were quite tough for us in terms of utilization and in terms of weather. We offset a significant portion of that. I mean, you heard on the prepared remarks that we had a 30 basis point headwind impact as a result of weather, but really we offset most of the headwinds in terms of the EPS impact.

So the $0.05 to $0.07, largely we feel good that that’s behind us and that’s essentially taken off the table. So we felt comfortable increasing our EPS by $0.10 at the midpoint. Now, we’re only in the second quarter here. We still have three quarters to go. Utilization was really strong, especially base business utilization in the first quarter. We’re expecting in the next three quarters that we go back to, I would say, more normal utilization, not what we saw in Q1. So that’s what our EPS range is also driven by. But I would say very pleased with the beat that we had in Q1 and taking the weather headwind off the table.

Jim Davis : Yeah. The only thing I’d add Ann, is that the volume growth was broad-based. We saw it across all physician channels and we saw it in health systems as well. So it did beat our internal expectations after a slow start in January. It came back very nicely in February and March and we finished strong.

Ann Hynes : Great. Thanks.

Operator: The next question comes from Kevin Caliendo of UBS. Your line is open.

Kevin Caliendo : Hey, thanks for taking my question. So, I wanted to ask a little bit about LDT. I’m sure you’re hoping that the ruling was going to come out before you reported, so that you can actually address it. But maybe talk a little bit, now that you’ve had some time to go over the initial proposal and maybe what you are expecting in the final proposal? Maybe can you let us know about the scope of the tests that you think are going to be included, and any sort of financial implications that you might have for fiscal ‘24? Did it change the way you were guiding? Is there anything in the guidance for this? And maybe how you think it plays out with regards to, are you going to try to get an injunction or anything like that through an ACLA?

Page 1 of 5